Intrinsic Value of S&P & Nasdaq Contact Us

Curis, Inc. CRIS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Curis, Inc. (CRIS) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 16 Buy, 2 Hold.

Analysts estimate Earnings Per Share (EPS) of $-6.93 and revenue of $0.01B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-6.88 vs est $-6.93 (beat +0.7%). 2025: actual $-0.58 vs est $-2.52 (beat +77%). Analyst accuracy: 0%.

CRIS Analyst Ratings

Buy
18
Ratings
16 Buy
2 Hold
Based on 18 analysts giving stock ratings to Curis, Inc. in the past 3 months
Rating breakdown
Buy
16 89%
Hold
2 11%
89%
Buy
16 analysts
11%
Hold
2 analysts
0%
Sell
0 analysts

EPS Estimates — CRIS

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$6.88 vs Est –$6.93 ▲ 0.7% off
2025 Actual –$0.58 vs Est –$2.52 ▲ 334.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — CRIS

84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.011B vs Est $0.010B ▲ 9.6% off
2025 Actual $0.009B vs Est $0.011B ▼ 21.7% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message